SEC Form 4 · accession 0001566044-18-000013
Yarrow Bioscience, Inc. · YARW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary Spellman
Officer — Chief Medical Officer
Period of report
Dec 10, 2018
Accepted (ET)
Dec 12, 2018 · 6:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001566044
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $5.51 | Dec 10, 2018 | A | 96,000 | A | — | Dec 10, 2028 | Common Stock | 96,000 | 96,000 | D |
Explanation of responses
- F1The shares subject to the option will vest over a period of four years, with 1/48th of the shares subject to the option vesting monthly.